According to filings with the U.S. Securities and Exchange Commission, Sydnexis is raising up to $8,499,630.00 in new funding. Sources indicate that as part of senior management President, Patrick Johnson played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Sydnexis
Sydnexis Inc., is a privately held clinical stage biopharmaceutical company based in San Diego that is developing a proprietary formulation for decreasing myopic progression in children. Sydnexis recently initiated a Phase 3 study testing its patented eyedrop formulation, SYD-101. Our Mission- Myopia is the most common eye disease in children and has experienced a dramatic increase in prevalence over the last 30 years. Myopia occurs in ~30-40% of children in the U.S. and E.U. and recent estimates suggest that number may be closer to 80% in Asia. Once considered a benign refractive condition myopia, even at low levels, is associated with numerous serious ophthalmic co-morbidities. Such ophthalmic co-morbidities include myopic macular degeneration, macular choroidal neovascularization, retinal detachment, glaucoma, and blindness. The greater the severity of myopia, the higher the risk of these ophthalmic co-morbidities later in life. Sydnexis was founded in San Diego in 2014 with the goal of developing a proprietary, stable, topical eyedrop to treat the progression of myopia in children.

To learn more about Sydnexis, visit http://sydnexis.com/

Contact:
Patrick Johnson, President
858-925-6172
https://www.linkedin.com/in/patrick-t-johnson/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.